Fasting blood sugar vs A1C: can someone explain why these numbers don't match if you're on a GLP-1 like semaglutide or tirzepatide

Understanding Fasting Blood Sugar and A1C Basics

As someone who has guided thousands through sustainable weight loss at CFP Weight Loss, I often see confusion around fasting blood sugar and A1C levels, especially for those using GLP-1 medications like semaglutide or tirzepatide. Fasting blood sugar measures your glucose after 8-12 hours without food, giving a snapshot—typically aiming for 80-130 mg/dL in managed diabetes. A1C, however, reflects your average blood glucose over the past 2-3 months, with targets usually below 7% for most adults.

These markers should align, but they frequently don't when you're on a GLP-1. This mismatch isn't a flaw in your body or the medication; it's rooted in how these drugs work with your hormones and metabolism. In my book, The CFP Method, I emphasize looking beyond single numbers to the full metabolic picture, particularly for those over 45 dealing with hormonal shifts and joint pain that limit traditional exercise.

How GLP-1 Medications Like Semaglutide and Tirzepatide Affect Glucose Readings

Semaglutide and tirzepatide slow gastric emptying, reduce appetite, and enhance insulin sensitivity while suppressing glucagon. This leads to lower post-meal spikes, which heavily influence A1C. However, your morning fasting blood sugar might remain elevated due to the dawn phenomenon—natural cortisol and growth hormone surges—or residual liver glucose production that these drugs don't fully suppress overnight.

Studies show A1C can drop 1.5-2.0% within months on these medications, even if fasting glucose hovers at 110-140 mg/dL. For middle-income adults managing diabetes, blood pressure, and obesity without insurance coverage, this is encouraging because the medications improve long-term averages more than isolated morning readings. The key: GLP-1s excel at flattening daily glucose curves, which A1C captures better than one fasting test.

Why the Numbers Diverge and What It Means for You

The divergence often stems from timing and physiology. Fasting blood sugar reflects one moment, potentially skewed by stress, poor sleep, or inconsistent medication timing—common challenges for busy 45-54 year olds. A1C integrates continuous glucose data, showing the true benefit of reduced variability from tirzepatide's dual GIP/GLP-1 action.

In practice, I've seen clients drop A1C from 8.2% to 6.1% while fasting glucose only falls from 160 to 125 mg/dL. This doesn't mean failure; it signals effective hormonal weight loss. Don't chase perfect fasting numbers at the expense of sustainable habits. Focus on consistent dosing, balanced plates with protein and fiber, and gentle movement like walking to ease joint pain.

Practical Steps to Interpret and Improve Your Results

Track both metrics alongside time-in-range from a continuous glucose monitor if possible. Review trends every 4-6 weeks with your provider. In The CFP Method, we advocate simple routines: 12-14 hour overnight fasts, not extreme intermittent fasting, paired with strength-building moves adaptable for joint issues. Prioritize sleep and stress management to tame dawn phenomenon. For those overwhelmed by conflicting advice, remember sustainable 1-2 pound weekly loss beats yo-yo dieting. If embarrassed about obesity struggles, know these medications level the playing field by addressing root hormonal resistance. Always consult your healthcare team before adjusting regimens.